 |
 Video: What is a Stock Split?
|
|
|
| ZIOPHARM Oncology is a biopharmaceutical company focused on discovering, developing and commercializing immuno-oncology platforms that utilize cell- and gene-based therapies to treat patients with cancer. Co.'s primary platform is referred to as Sleeping Beauty and is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that is intended to stably engineer T cells outside of the body for subsequent infusion. Co.'s second platform is referred to as Controlled IL-12 and is designed to stimulate expression of interleukin 12, a master regulator of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. According to our ZIOP split history records, ZIOP has had 0 splits. | |
|
ZIOP (ZIOP) has 0 splits in our ZIOP split history database.
Looking at the ZIOP split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ZIOP shares, starting with a $10,000 purchase of ZIOP, presented on a split-history-adjusted basis factoring in the complete ZIOP split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/25/2014 |
|
| End date: |
01/26/2022 |
|
| Start price/share: |
$3.35 |
|
| End price/share: |
$0.87 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-74.03% |
|
| Average Annual Total Return: |
-15.95% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,595.90 |
|
| Years: |
7.76 |
|
|
|
|
|
